c-Kit, a receptor tyrosine kinase, is involved in intracellular signaling, and the mutated form of c-Kit plays a crucial role in occurrence of some cancers. The function of c-Kit has led to the concept that inhibiting c-Kit kinase activity can be a target for cancer therapy. The promising results of inhibition of c-Kit for treatment of cancers have been observed in some cancers such as gastrointestinal stromal tumor, acute myeloid leukemia, melanoma, and other tumors, and these results have encouraged attempts toward improvement of using c-Kit as a capable target for cancer therapy.
AC710
From $95
AST 487
From $100
AZD2932
From $85
DCC-2618
From $95
Flumatinib mesylate
From $75
Imatinib
From $80
Imatinib Mesylate
From $80
Lenvatinib
From $80
Linifanib (ABT-869)
From $90
Masitinib
From $80
Masitinib mesylate
From $85
Motesanib (AMG-706)
From $95
Motesanib Diphosphate
From $80
MP-470
From $90
OSI-930
From $95
Pazopanib
From $80
Pazopanib Hydrochloride
From $80
SU14813 maleate
From $90
Tandutinib
From $75
Telatinib (BAY 57-9352)
From $90
Toceranib
From $90
Toceranib phosphate
From $85
Tyrphostin AG1296
From $115
XL184 (Cabozantinib)
From $80